Cargando…

Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies

Personalized treatment vs. standard of care is much debated, especially in clinical practice. Here we investigated whether overall survival differences in metastatic colorectal cancer patients are explained by tumor mutation profiles or by treatment differences in real clinical practice. Our retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Hendricks, Alexander, Amallraja, Anu, Meißner, Tobias, Forster, Peter, Rosenstiel, Philip, Burmeister, Greta, Schafmayer, Clemens, Franke, Andre, Hinz, Sebastian, Forster, Michael, Williams, Casey B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072525/
https://www.ncbi.nlm.nih.gov/pubmed/32046290
http://dx.doi.org/10.3390/cancers12020393
_version_ 1783506426989117440
author Hendricks, Alexander
Amallraja, Anu
Meißner, Tobias
Forster, Peter
Rosenstiel, Philip
Burmeister, Greta
Schafmayer, Clemens
Franke, Andre
Hinz, Sebastian
Forster, Michael
Williams, Casey B.
author_facet Hendricks, Alexander
Amallraja, Anu
Meißner, Tobias
Forster, Peter
Rosenstiel, Philip
Burmeister, Greta
Schafmayer, Clemens
Franke, Andre
Hinz, Sebastian
Forster, Michael
Williams, Casey B.
author_sort Hendricks, Alexander
collection PubMed
description Personalized treatment vs. standard of care is much debated, especially in clinical practice. Here we investigated whether overall survival differences in metastatic colorectal cancer patients are explained by tumor mutation profiles or by treatment differences in real clinical practice. Our retrospective study of metastatic colorectal cancer patients of confirmed European ancestry comprised 54 Americans and 54 gender-matched Germans. The Americans received standard of care, and on treatment failure, 35 patients received individualized treatments. The German patients received standard of care only. Tumor mutations, tumor mutation burden and microsatellite status were identified by using the FoundationOne assay or the IDT Pan-Cancer assay. High-risk patients were identified according to the mutational classification by Schell and colleagues. Results: Kaplan–Meier estimates show the high-risk patients to survive 16 months longer under individualized treatments than those under only standard of care, in the median (p < 0.001). Tumor mutation profiles stratify patients by risk groups but not by country. Conclusions: High-risk patients appear to survive significantly longer (p < 0.001) if they receive individualized treatments after the exhaustion of standard of care treatments. Secondly, the tumor mutation landscape in Americans and Germans is congruent and thus warrants the transatlantic exchange of successful treatment protocols and the harmonization of guidelines.
format Online
Article
Text
id pubmed-7072525
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70725252020-03-19 Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies Hendricks, Alexander Amallraja, Anu Meißner, Tobias Forster, Peter Rosenstiel, Philip Burmeister, Greta Schafmayer, Clemens Franke, Andre Hinz, Sebastian Forster, Michael Williams, Casey B. Cancers (Basel) Article Personalized treatment vs. standard of care is much debated, especially in clinical practice. Here we investigated whether overall survival differences in metastatic colorectal cancer patients are explained by tumor mutation profiles or by treatment differences in real clinical practice. Our retrospective study of metastatic colorectal cancer patients of confirmed European ancestry comprised 54 Americans and 54 gender-matched Germans. The Americans received standard of care, and on treatment failure, 35 patients received individualized treatments. The German patients received standard of care only. Tumor mutations, tumor mutation burden and microsatellite status were identified by using the FoundationOne assay or the IDT Pan-Cancer assay. High-risk patients were identified according to the mutational classification by Schell and colleagues. Results: Kaplan–Meier estimates show the high-risk patients to survive 16 months longer under individualized treatments than those under only standard of care, in the median (p < 0.001). Tumor mutation profiles stratify patients by risk groups but not by country. Conclusions: High-risk patients appear to survive significantly longer (p < 0.001) if they receive individualized treatments after the exhaustion of standard of care treatments. Secondly, the tumor mutation landscape in Americans and Germans is congruent and thus warrants the transatlantic exchange of successful treatment protocols and the harmonization of guidelines. MDPI 2020-02-08 /pmc/articles/PMC7072525/ /pubmed/32046290 http://dx.doi.org/10.3390/cancers12020393 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hendricks, Alexander
Amallraja, Anu
Meißner, Tobias
Forster, Peter
Rosenstiel, Philip
Burmeister, Greta
Schafmayer, Clemens
Franke, Andre
Hinz, Sebastian
Forster, Michael
Williams, Casey B.
Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies
title Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies
title_full Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies
title_fullStr Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies
title_full_unstemmed Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies
title_short Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies
title_sort stage iv colorectal cancer patients with high risk mutation profiles survived 16 months longer with individualized therapies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072525/
https://www.ncbi.nlm.nih.gov/pubmed/32046290
http://dx.doi.org/10.3390/cancers12020393
work_keys_str_mv AT hendricksalexander stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies
AT amallrajaanu stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies
AT meißnertobias stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies
AT forsterpeter stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies
AT rosenstielphilip stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies
AT burmeistergreta stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies
AT schafmayerclemens stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies
AT frankeandre stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies
AT hinzsebastian stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies
AT forstermichael stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies
AT williamscaseyb stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies